ADVISORY, April 01, 2016 --
What:
Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN), a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Robert Landry, Senior Vice President and Chief Financial Officer, will ring the Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Monday, April 4, 2016 – 9:15 a.m. to 9:30 a.m. ET
Regeneron Media Contact:
Alexandra Bowie
(914) 847-3407
[email protected]
Nasdaq MarketSite:
Emily Pan
(646) 441-5120
[email protected]
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page:
http://instagram.com/nasdaq
For livestream of ceremonies and events visit our YouTube Page:
http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit our Tumblr Page:
http://nasdaq.tumblr.com/
Webcast:
A LiveStream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.
About Regeneron Pharmaceuticals, Inc.
Regeneron (Nasdaq:REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
About NASDAQ-100 Index®
The NASDAQ-100 Index, launched in January 1985, is one of the most widely followed benchmarks in the world. The NASDAQ-100 Index is the basis of the PowerShares QQQ Trust (Nasdaq:QQQ) which aims to provide investment results that, before expenses, correspond with the NASDAQ-100 Index's performance. In addition, options, futures and structured products based on the NASDAQ-100 Index and the PowerShares QQQ Trust trade on various exchanges.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.6 trillion and nearly 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
-NDAQA-


Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 



